Corvus Pharmaceuticals（CRVS）株式概要
コルバス・ファーマシューティカルズ・インクは臨床段階にあるバイオ医薬品会社で、米国において免疫細胞の成熟と機能に重要なタンパク質を正確に標的とする製品候補の開発に従事している。 詳細
CRVS Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Corvus Pharmaceuticals, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$15.40 |
| 52週高値 | US$26.95 |
| 52週安値 | US$5.03 |
| ベータ | 0.87 |
| 1ヶ月の変化 | 9.22% |
| 3ヶ月変化 | 17.74% |
| 1年変化 | 196.72% |
| 3年間の変化 | 563.79% |
| 5年間の変化 | 593.69% |
| IPOからの変化 | 8.07% |
最新ニュース
Seeking Alpha • Aug 10
Corvus: Strong Buy Soquelitinib Q1 2027 Interim Futility Analysis And AD Drug Advancement
Summary Corvus Pharmaceuticals maintains a "Strong Buy" rating, driven by advancing soquelitinib in relapsed/refractory PTCL and moderate-to-severe atopic dermatitis [AD]. Company anticipates a pivotal interim futility analysis for its phase 3 PTCL trial in Q1 2027, representing a major inflection point. Positive phase 1 AD data and the initiation of the phase 2 SIERRA1 study, with topline results expected in Q3 2027, reinforce the pipeline’s potential. With $215.2M cash, company is funded into Q2 2028, minimizing near-term dilution risk and supporting ongoing clinical development. Read the full article on Seeking Alpha
ナラティブ更新 • Jun 26
CRVS: Phase 1 Atopic Dermatitis Data Will Drive Bullish Upside Potential
Analysts cut their 12 month price target on Corvus Pharmaceuticals stock from $51 to $42, citing updated fair value work that incorporates a higher discount rate, a revised future P/E assumption, and refreshed views on revenue growth and profit margins following recent bullish Street research coverage. What’s in the News for Corvus Pharmaceuticals Corvus Pharmaceuticals reported final data from a randomized, blinded, placebo-controlled Phase 1 trial of soquelitinib in 72 patients with moderate to severe atopic dermatitis, including patients who had previously received systemic therapy, showing safety and positive efficacy results.Recent updates
Seeking Alpha • Aug 10
Corvus: Strong Buy Soquelitinib Q1 2027 Interim Futility Analysis And AD Drug Advancement
Summary Corvus Pharmaceuticals maintains a "Strong Buy" rating, driven by advancing soquelitinib in relapsed/refractory PTCL and moderate-to-severe atopic dermatitis [AD]. Company anticipates a pivotal interim futility analysis for its phase 3 PTCL trial in Q1 2027, representing a major inflection point. Positive phase 1 AD data and the initiation of the phase 2 SIERRA1 study, with topline results expected in Q3 2027, reinforce the pipeline’s potential. With $215.2M cash, company is funded into Q2 2028, minimizing near-term dilution risk and supporting ongoing clinical development. Read the full article on Seeking Alphaナラティブ更新 • Jun 26
CRVS: Phase 1 Atopic Dermatitis Data Will Drive Bullish Upside Potential
Analysts cut their 12 month price target on Corvus Pharmaceuticals stock from $51 to $42, citing updated fair value work that incorporates a higher discount rate, a revised future P/E assumption, and refreshed views on revenue growth and profit margins following recent bullish Street research coverage. What’s in the News for Corvus Pharmaceuticals Corvus Pharmaceuticals reported final data from a randomized, blinded, placebo-controlled Phase 1 trial of soquelitinib in 72 patients with moderate to severe atopic dermatitis, including patients who had previously received systemic therapy, showing safety and positive efficacy results.
新しいナラティブ • Apr 02
Multiple Trial And Dilution Risks Will Shape Future Immunology Upside Potential
Catalysts About Corvus Pharmaceuticals Corvus Pharmaceuticals focuses on developing soquelitinib, a selective ITK inhibitor, for immune mediated diseases and cancers. What are the underlying business or industry changes driving this perspective?新しいナラティブ • Mar 19
Late Stage ITK Inhibitor Franchise Will Transform Immunology Pipeline Over The Long Term
Catalysts About Corvus Pharmaceuticals Corvus Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing soquelitinib, a selective ITK inhibitor, for cancers and immune inflammatory diseases. What are the underlying business or industry changes driving this perspective?
新しいナラティブ • Mar 05
Targeted Immunology Pipeline Will Position This Biotech For Multiple Long Term Catalysts
Catalysts About Corvus Pharmaceuticals Corvus Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing soquelitinib, an oral ITK inhibitor, for immune and inflammatory diseases and T cell lymphomas. What are the underlying business or industry changes driving this perspective?分析記事 • Nov 01
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...分析記事 • Aug 19
Is Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Trading At A 49% Discount?
Key Insights Corvus Pharmaceuticals' estimated fair value is US$10.34 based on 2 Stage Free Cash Flow to Equity Current...分析記事 • Jul 15
Corvus Pharmaceuticals (NASDAQ:CRVS) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. Indeed, Corvus...Seeking Alpha • Mar 28
Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials
Summary Corvus Pharmaceuticals' leading drug candidate is Soquelitinib, which has broad potential across PTCL, atopic dermatitis, and ALPS. Unfortunately, it seems Corvus' early AD data might have disappointed investors (at least initially). Still, Soquelitinib's promising Phase 3 PTCL trial results are due late 2026. Its PFS metrics might help it to differentiate from other standard chemotherapy treatments. As for Soquelitinib’s early AD results, I believe they were mostly positive, but they were based on limited data of just 28 days and 19 patients. Unfortunately, while Corvus' pipeline progress has been solid, they’re now running into dilution risks due to their short cash runway. Hence, I believe CRVS stock is a “Hold” now. Read the full article on Seeking AlphaSeeking Alpha • Mar 03
Corvus Pharmaceuticals: Small Market, Many Competitors, Low Cash Balance
Summary Corvus Pharmaceuticals' lead asset, Soquelitinib, shows promising early data in treating peripheral T cell lymphoma, solid tumors, and atopic dermatitis. Despite competitive clinical data, Corvus faces significant financial risks with limited cash reserves and a small, highly differentiated PTCL market. The company has a market cap of $259 million and a cash runway of approximately six quarters, raising concerns about funding future trials and commercialization. Given the financial constraints and competitive landscape, I recommend staying on the sidelines for now. Read the full article on Seeking Alpha分析記事 • Jan 13
We're Not Worried About Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Corvus...Seeking Alpha • Dec 18
Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting
Summary Positive results released from phase 1 study, using 100 mg twice daily oral dosing soquelitinib for the treatment of patients with Atopic Dermatitis; Several other cohorts testing higher dosing. The global atopic dermatitis market size is projected to reach $22.6 billion by 2031. Corvus is developing next-generation ITK inhibitors which are going to offer a more tailored approach to targeting specific immunological disorders. The company received a $12.7 million cash infusion from warrant exercises, bolstering its financial position and future development. Read the full article on Seeking AlphaSeeking Alpha • Nov 13
Corvus Pharmaceuticals: The Market Likes The Story
Summary Today, we take a look at Corvus Pharmaceuticals, whose stock has rocketed from under $2 a share this summer to around ten bucks a share. The company is advancing a couple of intriguing candidates within its developmental pipeline and recently kicked off a pivotal Phase 3 registrational study. Can the rally continue as the market increasingly buys into the story around Corvus, or is some profit taking on the horizon? An analysis around Corvus Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Sep 02
Corvus Pharmaceuticals: Soquelitinib's High Stakes In PTCL Therapy
Summary Corvus Pharmaceuticals is advancing soquelitinib, an ITK inhibitor, for peripheral T-cell lymphoma with a Phase 3 trial expected to start soon. Soquelitinib has shown promising Phase 1 data, particularly in patients with fewer prior therapies, but results in heavily pretreated patients are less encouraging. The drug's novel mechanism targets T-cell signaling to promote antitumor immunity, differentiating it from other treatments in PTCL. While soquelitinib's potential in PTCL is notable, the stock is best rated as a "hold" due to high uncertainty and the need for more conclusive clinical data. Read the full article on Seeking Alpha分析記事 • Mar 06
Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. Indeed, Corvus...分析記事 • Oct 23
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...分析記事 • May 16
Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • Dec 05
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Sep 26
Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China
Clinical-stage biopharma Corvus Pharmaceuticals (NASDAQ:CRVS) on Monday said an investigational new drug application to start a phase 1/1b trial of monoclonal antibody mupadolimab had been approved by China's drug regulator. The study was approved by the Center for Drug Evaluation of the China National Medical Products Administration, and will be conducted by Angel Pharmaceuticals, CRVS' partner in the Asian country. Mupadolimab is being evaluated for the treatment of patients with relapsed refractory non-small cell lung cancer and head and neck squamous cell cancers. Angel Pharma, a privately-held biopharma, was co-founded by CRVS to develop its pipeline in greater China. Angel Pharma licensed the rights from CRVS to develop, make and commercialize mupadolimab in greater China, Corvus (CRVS) said in a statement. CRVS stock +5% to $0.76 after hours.分析記事 • Aug 14
We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...分析記事 • Apr 05
Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...分析記事 • Dec 15
We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Dec 10
Checking In On Corvus Pharmaceuticals
Today, we look at Corvus Pharmaceuticals, a company that has multiple candidates in development. The stock has had a roller coaster ride so far in 2021. A full investment analysis is presented in the paragraphs below.Seeking Alpha • Sep 22
Corvus: Surging On AstraZeneca CD73 Success With Key Data Readout Looming
Corvus stock has made spectacular gains across the past week, rising from a price of $2.3 to $8.5 - a 270% gain. Last week, AstraZeneca's Oleclumab - an anti-CD73 therapy - substantially improved the risk of death in combo with IMFINZI in NSCLC. Corvus' Mupadolimab is an anti-CD73 monoclonal antibody and hopes are high that it can show similar efficacy to Oleclumab. Corvus recently discontinued the development of Mupadolimab as a COVID therapy and resumed trials of the drug in head and neck cancer. Data from that trial, and an expansion cohort in combo with Merck's Keytruda, ought to read out this year - a potentially exciting catalyst. Corvus deserves its recent uplift, in my view, but still has much to prove.分析記事 • Aug 26
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • May 08
Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...分析記事 • Feb 19
The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares
Investors who take an interest in Corvus Pharmaceuticals, Inc. ( NASDAQ:CRVS ) should definitely note that the...分析記事 • Feb 07
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...分析記事 • Dec 16
Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like
Every investor in Corvus Pharmaceuticals, Inc. ( NASDAQ:CRVS ) should be aware of the most powerful shareholder groups...株主還元
| CRVS | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | 2.3% | 6.2% | -0.8% |
| 1Y | 196.7% | 46.3% | 20.5% |
業界別リターン: CRVS過去 1 年間で46.3 % の収益を上げたUS Biotechs業界を上回りました。
リターン対市場: CRVS過去 1 年間で20.5 % の収益を上げたUS市場を上回りました。
価格変動
| CRVS volatility | |
|---|---|
| CRVS Average Weekly Movement | 6.9% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: CRVS 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: CRVSの 週次ボラティリティ は、過去 1 年間で25%から7%に減少しました。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2014 | 37 | Rick Miller | www.corvuspharma.com |
コルバス・ファーマシューティカルズ・インクは臨床段階にあるバイオ医薬品企業で、米国では免疫細胞の成熟と機能に重要なタンパク質を正確に標的とする製品候補の開発に従事している。同社の主要製品候補は、インターロイキン2誘導性T細胞キナーゼ（ITK）の選択的共有結合阻害剤であるソケリチニブ（CPI-818）であり、末梢性T細胞リンパ腫、アトピー性皮膚炎、膿疱性汗腺炎、自己免疫性リンパ増殖症候群、固形癌単剤療法、喘息の治療薬として多施設共同第1b/2相臨床試験中である。また、A2A受容体の経口低分子拮抗薬であるシフォラデナント（CPI-444）を開発中で、腎細胞癌の一次治療薬として臨床第2相試験中であり、ヒト化モノクローナル抗体であるムパドリマブ（CPI-006）は非小細胞肺癌の治療薬として臨床第1相試験中である。また、モナシュ大学とはCXCR2に対するヒト疾患治療用抗体の研究・開発・商業化に関するライセンス契約を、ヴァーナリス（R&D）社とはシフォラデナントを含む特定のアデノシン受容体拮抗薬を含む製品の開発・製造・商業化に関するライセンス契約を、スクリプス社とはムパドリマブの開発・商業化に関するライセンス契約を締結している。コルバス・ファーマシューティカルズ・インクは2014年に法人化され、カリフォルニア州サウスサンフランシスコを拠点としている。
Corvus Pharmaceuticals, Inc. 基礎のまとめ
| CRVS 基礎統計学 | |
|---|---|
| 時価総額 | US$1.25b |
| 収益（TTM） | -US$54.13m |
| 売上高(TTM) | n/a |
0.0x
P/Sレシオ-23.9x
PER（株価収益率CRVS は割高か？
公正価値と評価分析を参照収益と収入
| CRVS 損益計算書（TTM） | |
|---|---|
| 収益 | US$0 |
| 売上原価 | US$0 |
| 売上総利益 | US$0 |
| その他の費用 | US$54.13m |
| 収益 | -US$54.13m |
直近の収益報告
Jun 30, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -0.64 |
| グロス・マージン | 0.00% |
| 純利益率 | 0.00% |
| 有利子負債／自己資本比率 | 0% |
CRVS の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/19 10:57 |
| 終値 | 2026/08/19 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Corvus Pharmaceuticals, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14
| アナリスト | 機関 |
|---|---|
| Etzer Darout | Barclays |
| Dane Leone | BTIG |
| Li Wang Watsek | Cantor Fitzgerald & Co. |